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Introduction
FasL (Fas Ligand: TNF receptor superfamily, member 6) is key molecule in normal immune development, homeostasis, modulation, and function. FasL ligates to its receptor Fas (CD95), resulting in receptor oligomerization and subsequent recruitment of the adaptor protein FADD and caspases (procaspase-8 or -10). Together, these form the death-inducing signaling complex and in turn activate the apoptosis signaling pathway (1) . Tumor cells express FasL to counterattack tumor-infiltrating T cells, which results in immune escape (2) (3) (4) (5) . However, many cancer cells resist Fas-mediated apoptosis via overexpression of apoptosis-signaling inhibitors, such as c-FLIP L , which is highly competitive and homologous to procaspases-8 and -10 but does not induce further apoptotic signaling by procaspases (6) (7) (8) . Both in vitro and in vivo studies have provided overwhelming evidence of activation of tumor progression by tumor-derived FasL via the AKT, NF-κB, and JNK signaling pathway (8) (9) (10) (11) (12) (13) (14) (15) (16) . Tumor size and the number of tumor nodules have also been significantly reduced in mice injected with FasL antibody (9) . This suggests that tumor-derived FasL may counterattack T cells to reduce anti-cancer ability, thus promoting tumor malignancy.
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Chinese population was associated with an increased risk of different human cancers, including those of the cervix, lung, esophagus, breast, and pancreas (18) (19) (20) (21) (22) .
A higher prevalence of T cell apoptosis in the FasL -844CC carrier was expected to cause a greater enhancement of tumor progression and metastasis via immune escape (19, 21) . In fact, the FasL protein was over-expressed in different tumors, including colon, breast, liver, gastric, ovary, and lung carcinomas (2, 5, (23) (24) (25) (26) (27) (28) (29) . Among these, FasL expression was more prevalent in advanced ovarian tumors, but was not related to the patients' clinical outcome (4) . In cervical cancers, FasL expression tended to be related to tumor stage and patients had a poorer clinical outcome (30) . Therefore, the prognostic significance of FasL polymorphism in non-small cell lung cancer (NSCLC) should be further identified.
In the present study, we hypothesized that lung tumors with FasL -844CC genotype might have higher FasL expression than those with FasL -844TT+TC genotype. High immediately frozen at surgery and kept at −80 °C until processed. All patients were informed and had provided written consent. The study was approved by the Institutional Review Board. Cancer relapse data were obtained by chart review and confirmed by thoracic surgeons. Clinical parameters, OS and RFS data were collected from chart reviews (32 patients had no relapse data) and the Taiwan Cancer Registry, Department of Health, Executive Yuan, ROC. For co-culture experiments, blood samples were obtained from 11 healthy male volunteers working in our university between the ages of 22 and 32 years (mean ± SD = 26.6 ± 3.1).
Genomic DNA extraction, RNA extraction and cDNA synthesis Genomic DNA was extracted by conventional methods. Surgically resected normal tissues adjacent to the lung tumor were prepared by using proteinase K digestion and phenol-chloroform extraction, followed by ethanol precipitation.
Research. Total RNA was extracted from 174 available lung tumor tissues using TRIzol reagent (Invitrogen, USA). First-strand cDNA synthesis in the presence of random primers was performed using a high-capacity cDNA reverse transcription kit (Applied Biosystems, USA) according to the manufacturer's instructions.
PCR-RFLP Analysis for FasL -844T/C Genetic Polymorphism
Genotypes of FasL -844T/C were determined by polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) as described by Sun et al. (20) . PCR amplification products from 100 samples were randomly selected for direct sequencing to confirm the genotype analysis by PCR-RFLP.
Real-time PCR
Real-time PCR amplification of cDNA samples was performed with an ABI 7500 Real time PCR System (Applied Biosystems, USA) and SYBR Green dye to quantify FasL mRNA transcripts. Real-time PCR primers were as follows: for FasL transcripts, Biosystems, USA). The cut-off value was defined by the medium value for high and low mRNA expression.
Immunohistochemical staining
Immunohistochemical staining to evaluate FasL and c-FLIP L expression in tumor tissue was performed on 87 whole-mount paraffin sections of lung cancer specimens. Anti-FasL Immunohistochemical staining scores were defined as previously described (26) .
Direct sequencing
Tumor DNA was amplified and used for determining p53 mutation by direct sequencing with an Applied Biosystems 3100 Avant Genetic Analyzer (Applied Biosystems, USA) as described by Cheng et al. (32) .
Cell culture
H1355 and A427 lung cancer cells were purchased from The American Type Culture Collection (ATCC, USA). TL4 and TL13 lung cancer cells were established from pleural effusions as described previously (32) . The pathological diagnosis of TL13 was lung adenocarcinoma of a 79-year-old male nonsmoker with T 4 N 3 M 1 . H1355 and A427 were maintained in DMEM medium (Gibco TM , USA) with 10% FBS, 2 mM glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin. TL4 and TL13 were maintained in RPMI medium (Gibco TM , USA) with 10% FBS, 2 mM glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin.
Plasmid construction and transfection reaction
RNA interference was performed by expression of small hairpin RNA (shRNA) to target 
Peripheral blood monocyte isolation and co-culture experiments
Peripheral blood monocytes (PBMCs) from healthy donors were isolated by Ficoll-Paque (GE Healthcare, Sweden) density-gradient centrifugation as described previously (21) . The PBMCs were used for the determination of cancer cell-induced T cell apoptosis by co-culture with lung cancer cells (TL4, A427, H1355, and TL13) at a ratio of 10: 1 for 36 hrs. The PBMCs were then collected for analysis of T cell apoptosis by flow cytometry.
Flow cytometry analysis
Research. 
Statistical Analysis
The Student's t test and Chi-square test were applied for continuous or discrete data analysis. The associations between the FasL -844T/C genotype and patient survival were estimated using the Kaplan-Meier method and assessed using the log-rank test. Potential confounders were adjusted by Cox regression models, with the FasL -844T/C genotype fitted as indicator variables. All statistical analyses were done using the SPSS statistical software program (version 11.0; SPSS, Inc., Chicago, IL). All statistical tests were two-sided and P values < 0.050 were considered to be statistically significant. 39.6% for stage I, P = 0.008; Table 1 ). Patients with the FasL -844CC genotype were found to be more prone to tumor relapse than those with the FasL -844TT+TC genotype (62.1% for CC vs. 44.1% for TT+TC, P = 0.001). FasL -844CC was not associated with other clinic-pathological parameters including age, gender, smoking status, and tumor type (Table 1) . These results suggest that the FasL-844CC genotype may confer greater tumor progression and relapse than the FasL-844TT+TC genotype.
Expression of FasL mRNA and protein in lung tumors was higher in FasL -844CC carriers than in FasL -844TT+TC carriers
To verify whether the polymorphic CAAT/enhancer-binding protein β element in the Table 2 ). These results suggest that FasL -844T/C polymorphism in the promoter region may be responsible for FasL expression in lung tumors.
Greater T cell apoptosis induced by FasL expression may result in greater immune escape in FasL -844CC carriers
Previous reports have shown that PBMCs with the FasL -844CC genotype undergo more T cell apoptosis than those with FasL -844 TT+TC genotype (19, 21) . Therefore, the immune evasion induced by FasL overexpression in tumor tissues may promote tumor progression and metastasis, leading to poor clinical outcomes for the patients. We tested this possibility, by first determining the FasL -844T/C genotype in a panel of lung cancer cells by a direct sequencing. We selected H1355 and TL13 cells harbored FasL -844CC genotype and TL4 and A427 cells that harbored the FasL -844TT for this study. As expected, H1355 and TL13 cells carrying FasL -844CC genotype had a higher level of FasL expression than did TL4 and A427 cells carrying the FasL -844TT genotype ( Figure   1A ). We also verified whether lung cancer cells carrying different FasL -844 genotypes could induce different degree of T cell apoptosis. PBMCs from 11 healthy donors were co-cultured with the four lung cancer cell types, and T cells were then gated for apoptotic analysis. As shown in Fig.1B , a greater degree of T cell apoptosis was found in PBMCs 
Discussion
A series of epidemiological studies conducted by Lin's group indicated that subjects with the FasL -844CC genotype have a higher cancer risk than those with the FasL -844TT+TC genotype, including increased risk of esophageal, cervical, lung, breast, and pancreatic carcinomas (18) (19) (20) (21) (22) . However, the FasL -844T/C genotype was not associated with lung cancer risk in our case-control study (385 cases and 308 controls), which might be explained by differences in the studied case populations (FasL -844CC genotype:
61.2% for Chinese vs. 46.4% for Taiwanese). Nevertheless, a similar distribution of the FasL -844CC genotype was observed in control subjects (47.3% for Chinese vs. 46.4% for Taiwanese). In the present study, we investigated a large population and showed that FasL -844T/C polymorphism may predict both OS and RFS in NSCLC. However, the prognostic significance of FasL -844T/C polymorphism in NSCLC was not shown in the Korean population (33) . Surprisingly, the distribution of FasL -844 genotypes in two studies reported by Park's group was quite different (TT/TC/CC: 51.6%/41.8%/6.6% vs.
8.1%/39.2%/52.8%) (33, 34) . The FasL -844T/C polymorphism in the promoter region was associated with FasL expression in lung tumors (Table 2) . Therefore, higher FasL expression levels in T cells and lung cancer cells with the FasL -844CC genotype were expected to contribute to immune escape and tumor malignancy. Previous reports have indicated that T cells with the FasL -844CC genotype had higher FasL expression compared with those with the FasL -844TT+TC genotype, which results in a high rate of T cell apoptosis when these are co-cultured with cervical and breast cancer cells (19, 21) .
In the present study, co-culture of PBMCs from healthy donors with lung cancer cells 
analysis. Shorter OS and RFS periods were found for patients with higher FasL mRNA expression (HR = 2.223, 95% CI, 1.473-3.356, P < 0.001 for OS; HR = 2.028, 95% CI, 1.351-3.046, P = 0.001 for RFS). In addition, poorer OS and RFS were seen in patients with a high immunostaining score for FasL (score ≥ 100) than in those with low FasL immunostaining score (score < 100) (HR = 2.024, 95% CI, 1.135-3.612, P = 0.017 for OS; HR = 1.809, 95% CI, 1.010-3.242, P = 0.046 for RFS). These results further support our hypothesis that FasL -844T/C promoter polymorphism may be a helpful predictor of patient survival outcomes.
We also examined whether the greater T cell apoptosis seen in FasL -844CC carriers 
tumor cells. In our cases, FasL expression was positively correlated with c-FLIP L , which suggests that c-FLIP L may be an important apoptotic inhibitor that blocks FasL-induced apoptosis in NSCLC (Table 3 ). In addition, c-FLIP L expression was higher in p53 wild-type tumors than in p53 mutated tumors (Table 3) Staining intensity: 0-1 (undetectable to low) and 2-3 (moderate to high), N = 87.
